Given wheat global shortages and high prices, Lavie foresees continued strong demand for its bio-inoculant result™ and plans increased production for 2023 growing season Rehovot, Israel – May 11, 2022 — Lavie Bio Ltd., a subsidiary of Evogene Ltd., (NASDAQ: EVGN, TASE: EVGN) and a leading ag-biologicals company focusing on improving food quality, sustainability,
Read moreAdvancement to the pre-commercial stage follows positive results from three consecutive years of vineyard trials for fruit rot diseases Rehovot, Israel – December 14, 2021 – Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products, and a subsidiary of Evogene
Read moreresult™ inoculant initially introduced for spring wheat in North Dakota, following positive four-year field trials Rehovot, Israel – November 3, 2021 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products,
Read moreCommercialization targeted for 2022 for spring wheat initially Rehovot, Israel and Berthold, ND, USA – September 29, 2021 — Lavie Bio Ltd. (Lavie), a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and United
Read moreThis appointment continues Lavie Bio’s advancement of its commercial pipeline, focusing on its planned product launches starting 2022 Rehovot, Israel – May 25th, 2021 – Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ:
Read more